GlassScriptPhysician profile
Shelly Levinstein
NPI 1023348950
$3,006.23
in general payments reported to CMS, 2019-2025
26 companies · $834 in 2025
The $834 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $672 · 2022: $402 · 2023: $479 · 2024: $619 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,918.74 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $450.48 | 2021-2025 | Farxiga, Lokelma |
| Ardelyx, INC. | $250.85 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Glaxosmithkline, LLC. | $241.59 | 2021-2024 | Benlysta, Jesduvroq |
| Amgen INC. | $226.47 | 2021-2023 | Parsabiv, Tavneos |
| Vifor Pharma, INC. | $206.70 | 2021-2025 | Veltassa |
| Akebia Therapeutics INC | $181.32 | 2021-2025 | Vafseo |
| Travere Therapeutics, INC. | $179.10 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $177.67 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $158.23 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $149.25 | 2021-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $134.21 | 2024-2025 | Acthar, Terlivaz |
| Kyowa Kirin, INC. | $113.22 | 2023-2025 | Crysvita |
| Opko Pharmaceuticals, LLC | $109.04 | 2021-2025 | Rayaldee |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $86.12 | 2021-2024 | Jynarque |
| Otsuka America Pharmaceutical, INC. | $53.43 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $46.92 | 2021-2022 | |
| Baxter Healthcare | $37.01 | 2024 | Renal - Chronic |
| Alexion Pharmaceuticals, INC. | $33.41 | 2021-2023 | Ultomiris |
| Apellis Pharmaceuticals, INC. | $27.69 | 2025 | Empaveli |
| Ani Pharmaceuticals, INC. | $26.34 | 2025 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $24.16 | 2025 | |
| Biomerieux INC | $21.00 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.86 | 2023 | Jardiance |
| Novo Nordisk INC | $19.43 | 2025 | Ozempic |
| Medtronic, INC. | $18.75 | 2024 | |
| Lilly USA, LLC | $13.98 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelly Levinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.